This invention relates to a surgical kit for treating glaucoma in a patient. The invention relates also to a method for treating glaucoma in a patient. More specifically, the invention relates to a surgical kit and method for treating glaucoma in a patient by diverting aqueous fluid from a chamber of the eye to the subconjunctival space of the patient.
Glaucoma is an ocular disease characterised by the presence of raised intraocular pressure (IOP) causing irreversible damage to the optic nerve. The ocular globe of the eye has a tough outer layer comprised of the sclera and the cornea. The internal areas of the eye are separated into the anterior segment and the posterior segment. The anterior segment comprises the anterior and posterior chambers of the eye filled with aqueous fluid, and the posterior segment comprises the vitreous chamber filled with vitreous gel. The cornea merges into the sclera at a juncture referred to as the limbus. The limbus comprises an approximately 2 mm annular region surrounding the cornea, which includes a 1 mm so-called “blue zone” adjacent the cornea and a 1 mm so-called “white zone” adjacent the sclera. The trabecular meshwork lies under the limbus within the anterior chamber angle. A portion of the sclera is covered by a thin tissue called Tenon's membrane (also called Tenon's capsule), which envelopes the bulb of the eye from the optic nerve to the ciliary region. Near its front, Tenon's membrane blends into the conjunctiva where it is attached to the ciliary region of the eye.
The ocular globe maintains an internal pressure known as the intraocular pressure which normally varies between 10 mmHg and 21 mmHg. The intraocular pressure needs to be controlled within a defined range in order for the eye to function normally. The intraocular pressure is regulated by maintaining a balance between volumes of aqueous fluid produced and drained from the anterior segment of the ocular globe. Aqueous fluid is produced at a rate of about 2 to 3 micromillimetres per minute by the ciliary body and drained through the trabecular meshwork and uveoscleral pathways at variable rates. If an impairment occurs in the amount of aqueous fluid drained from the ocular globe, then the intraocular pressure becomes too high. The presence of raised intraocular pressure results in a large pressure differential across the lamina cribrosa (translaminar pressure). This causes damage to the optic nerve head known as glaucoma. Glaucoma causes irreversible visual field defects. These defects enlarge until a patient's field of view is severely restricted. In the end stage of the disease, total vision loss occurs. Glaucoma is a leading cause of blindness worldwide. If the intraocular pressure remains very high, the eye can become persistently painful and may need to be removed.
Current medical, laser and surgical treatment options for glaucoma are aimed at lowering intraocular pressure. Glaucoma which is difficult to control through first line therapies such as topical medications and laser therapy is known as refractory glaucoma. Refractory glaucoma is often managed by glaucoma drainage device implantation to create an additional aqueous outflow pathway into the subconjunctival space.
The general technique for subconjunctival glaucoma drainage device implantation includes the following steps:
Aqueous fluid draining through the tube into the subconjunctival space creates a fluid blister between the sclera and the tenons/conjunctiva known as a bleb.
It is preferable for the scleral channel created to have the smallest dimension achievable to reduce the invasiveness of the procedure. The initial angle of the scleral channel needs to be sufficiently parallel to the ocular globe so as to pass along the sclera without prematurely penetrating the eye, however the final angle at which the scleral channel enters the anterior chamber needs to be approximately in the plane which bisects the angle between the iris and the cornea so that the tube entering the eye does not touch the corneal endothelium or iris tissue which could cause corneal endothelial decompensation or tube blockage respectively. Additionally, the point at which the scleral channel enters the anterior chamber needs to be at the region of the trabecular meshwork. Entering anterior to this may result in the tube damaging corneal endothelial stem cells and entering posterior to this may result in bleeding from the ciliary body. In the early stages following surgery, fluid leakage may occur between the tube and the scleral channel. Fluid leakage may result in IOP dropping below 5 mmHg which causes a condition known as hypotony. Hypotony may cause complications such as maculopathy and choroidal effusion. In the later stages, glaucoma devices may tend to erode through surrounding tissues which creates a risk for device migration and exposure. One factor which determines the likelihood for erosion of a device is the maximal dimension of the device. A glaucoma device implanted within a scleral channel needs to be sufficiently small so as to reduce invasiveness and the risk of erosion, but also sufficiently large so as to create an effective fluid seal within the scleral channel.
The MicroShunt kit (described in U.S. Pat. No. 9,101,444) comprises a surgical kit for treating elevated ocular pressure, including a surgical instrument having a needle body used to form a surgical passage through ocular tissue and a shunt defining a duct, for diverting aqueous fluid from the anterior chamber of the eye of a patient. The shunt consists of a straight tube of about 8 mm in length with a pair of sealing tabs extending in a common plane radially outwardly. A scleral channel is created from approximately 3 mm from the limbus radially along the sclera until the anterior chamber is entered using the needle body. The distal end of the tube is passed through the scleral channel to enter the anterior chamber. The sealing tabs are positioned in the scleral channel to create a fluid seal between the tube and surrounding scleral tissue. The proximal end is then left lying in the subconjunctival space to create a bleb. The sealing tabs have a maximal cross-sectional dimension that is greater than a maximal cross-sectional dimension of the needle body.
The design of the MicroShunt kit results in sealing tabs with a larger cross-sectional dimension than the instrument used to create the scleral channel. This increases the maximal cross-sectional dimension of the device and therefore the invasiveness and risk of erosion and migration. The kit furthermore includes the use of a needle body for creating a scleral channel. Needle bodies are known to be cumbersome when used during the creation of a scleral channel. This is due to the single bevelled tip and round body. The single bevel results in the instrument tending to track in the direction of the bevel when creating a channel. This creates difficulty for the surgeon when trying to maintain an accurate channel depth within the thin scleral wall. Additionally, the round body of the needle creates a round channel within the sclera which is more prone to aqueous fluid leakage.
It is an object of the present invention to provide a surgical kit and a method for treating glaucoma which addresses the abovementioned shortcomings of existing ocular shunt devices and kits for use in the treatment of glaucoma.
In this specification, the term “distal” means in the direction of the eye of a patient or away from a user of the shunt of the surgical kit, while the term “proximal” means in the direction away from the eye of the patient or towards the user of the shunt.
According to a first aspect of the invention there is provided a surgical kit for treating glaucoma in a patient, the surgical kit comprising:
a surgical instrument having a flat cutting blade for creating a passageway through scleral tissue, the flat blade having a first maximal cross-sectional dimension;
The cutting blade of the surgical instrument may have bevelled cutting surfaces at opposite sides of the cutting blade at a tip region of the cutting blade. The bevelled cutting tip may have a length of approximately 2 mm.
The elongate duct of the shunt may have a proximal portion defining a proximal end of the elongate duct, the proximal portion being locatable externally of the scleral passageway.
The distal portion of the elongate duct may have a distal lumen defining a distal part of the fluid passageway and the proximal portion may have a proximal capillary lumen which is in fluid flow communication with the distal lumen, the proximal lumen having an internal diameter which is relatively smaller than an internal diameter of the distal lumen so as to reduce a flow rate of aqueous humor and regulate pressure along the proximal capillary lumen sufficient to prevent hypotony.
The chamber of the eye in which the shunt is implanted may be the anterior chamber, the posterior chamber or the vitreous chamber of the eye.
In a particular embodiment of the invention, the proximal portion of the elongate duct may be releasably connected to the distal portion of the elongate duct. In another embodiment of the invention, the proximal portion of the elongate duct may be fixedly connected to the distal portion of elongate duct.
The fixation body of the shunt may be slidably located on the distal portion of the elongate duct for fixing the distal portion of the duct within the scleral channel at a desired position determined by a required length of the shunt.
The fixation body may be frictionally located on the distal portion of the elongate duct in an arrangement wherein a coefficient of friction acting between the fixation body and the elongate duct is sufficient to adequately resist movement of the fixation body relative to the elongate duct when the elongate duct is implanted in the scleral passageway of the patient yet permits sliding displacement of the fixation body relative to the elongate duct when a moderate force is applied to the fixation body by a surgeon.
The fixation body may define an internal passage within which the elongate duct is received. The fixation body may be located on the elongate duct in an interference fit wherein an internal diameter of the fixation body is slightly less than an external diameter of the distal portion of the elongate duct.
The fixation body may have a pair of laterally-extending flanges which project outwardly from opposite sides thereof.
The fixation body may have a convexly rounded lower surface and a substantially flat upper surface.
The fixation body may be of a rigid construction.
The fixation body may define a curved internal passage in which the elongate duct is received. The curvature of the internal passage causes bending of the elongate duct received therein, thereby directing the distal end away from the corneal endothelium and towards the iris plane of the patient.
According to a second aspect of the invention there is provided a surgical method for treating glaucoma in a patient, the surgical method comprising:
The surgical method may include, prior to creating the passageway using the cutting blade, marking a point on the sclera in the pocket between the conjunctival/tenon's complex and the sclera at a predetermined distance from the limbus which may be approximately 3 mm from the limbus.
The surgical method may include creating the passageway through scleral tissue, from the predetermined position on the sclera to enter the chamber of the eye in a single step.
Alternatively, the surgical method may include creating the passageway through scleral tissue, from the predetermined position on the sclera to enter the chamber of the eye in three steps as follows:
Further features of the invention are described in more detail hereinafter, by way of a non-limiting example of the invention, with reference to and as illustrated in the accompanying diagrammatic drawings. In the drawings:
A surgical kit for treating glaucoma by lowering intraocular pressure in an eye of a patient, is described and illustrated. Anatomic details of a human eye are illustrated in
The surgical kit comprises, broadly, a surgical instrument 50 for creating a passageway though scleral tissue and a shunt 10 which can be located in the passageway for diverting aqueous fluid from a chamber of the eye.
With reference to
The elongate duct 12 has a distal end 18 and an opposite proximal end 20, the distal end 18 being implantable in the relevant chamber of the eye. The elongate duct has a distal portion 22 defining the distal end of the duct, which is locatable in the scleral channel of the patient, the distal portion being deformable so as to permit the distal portion to conform to anatomical structures of the eye of the patient. The distal portion is also severable, allowing a surgeon to cut the distal portion to a desired length corresponding to the anatomical dimensions of the patient's eye and required bleb position. As is illustrated in
The elongate duct 12 further has a proximal portion 24 having a rigid construction, which defines the proximal end of the elongate duct.
The distal portion 22 has a distal lumen 26 defining a distal part of the fluid passageway and the proximal portion 24 has a proximal capillary lumen 28 which is in fluid flow communication with the distal lumen, the proximal lumen having an internal diameter which is relatively smaller than an internal diameter of the distal lumen so as to reduce a flow rate of aqueous humor along the proximal capillary lumen.
The shunt is configured to resist aqueous fluid flow at flow rates of between 1.5 to 3.0micromillimetres per minute through the shunt using the Haigen Pouseille equation and a viscosity factor of 7.042 cP and more specifically, about 2 micromillimetres per minute.
The distal lumen has a diameter of between 0.12 mm and 0.3 mm.
The proximal capillary lumen has a diameter of between 0.035 mm and 0.06 mm.
The distal portion has a length of between 4 mm and 30 mm after cutting by the surgeon.
The proximal portion has a length of between 1 mm and 8 mm. The distal portion is configured to provide negligible fluid flow resistance less than 1 mmHg while the proximal capillary portion is configured to provide significant fluid flow resistance of between 4 mmHg and 12 mmHg.
In a particular embodiment of the invention, the proximal portion of the elongate duct is releasably connected to the distal portion of the elongate duct. In another embodiment of the invention, the proximal portion of the elongate duct is fixedly connected to the distal portion of elongate duct.
The proximal portion of the elongate duct has an oval shape when viewed in cross section. The proximal portion has a curvature that conforms to that of an anatomical curvature of the ocular globe.
The fixation body 14 of the shunt forms an effective seal with surrounding scleral tissue. The fixation body is slidably located on the distal portion of the elongate duct 12 for fixing the distal portion 22 of the duct within a channel created in scleral tissue at a desired position determined by a required length of the shunt as will be explained in more detail hereinbelow.
The fixation body 14 is frictionally located on the distal portion 22 of the elongate duct in an arrangement wherein a coefficient of friction acting between the fixation body and the elongate duct is sufficient to adequately resist movement of the fixation body relative to the elongate duct following implantation yet permit sliding displacement of the fixation body relative to the elongate duct when a force is applied to the fixation body by a surgeon during implantation. The elongate duct is deformed slightly inwardly in the region where it is engaged by the fixation body.
The fixation body defines a curved internal passage 30 within which the distal portion of the elongate duct is received. The internal passage 30 of the fixation body and the distal portion of the elongate duct are cylindrical. The curvature of the internal passage 30 is configured so as to cause bending of the elongate duct when the elongate duct is received therein, thereby to resist displacement of the shunt within a scleral channel created within scleral tissue and direct the distal end away from the corneal endothelium and towards the iris plane of the patient.
With reference to
The distal portion 22 of the elongate duct 12 has a second maximal cross-sectional dimension DMAX2 which is less than the first maximal cross-sectional dimension DMAX1.
The fixation body 14 has a third maximal cross-sectional dimension DMAX3 which is greater than the second maximal cross-sectional dimension DMAX2 but less than the first maximal cross-sectional dimension DMAX1.
The use of a flat cutting blade for creating the passageway in the scleral tissue for the elongate duct of the shunt, is minimally invasive, reduces the risk of aqueous fluid leakage and allows the use of a fixation body having a relatively small cross-sectional dimension DMAX3 which is less than the width of the cutting blade (DMAX1).
With reference to
With specific reference to
An internal diameter of the internal passage 30 of the fixation body is slightly less than an external diameter of the distal portion of the elongate duct, causing the fixation body to be located on the distal portion 22 of the duct 12 in an interference fit permitting sliding displacement of the fixation body when sufficient force is applied to the fixation body in order to overcome frictional forces holding the fixation body on the distal position.
With reference to
With reference to
In
With reference to
With reference to
The shunt 10 provides an extended length of deformable tube with a fixation body slidably located thereon so as to allow a surgeon to adjust the position of the fixation body along the elongate duct to thereby adjust the length of the shunt to the anatomical dimensions of the eye of a patient and provide for optimal positioning of a bleb into which aqueous humor can drain.
The proximal portion of the elongate duct provides the shunt with a capillary valve, while the distal portion of the elongate duct may be cut so as to adjust the length of the shunt without affecting the capillary valve or altering the resistance to fluid flow along the fluid passageway of the shunt significantly.
The interference fit of the fixation body on the distal portion of the shunt provides for resistance to migration of the fixation body along the elongate duct when the shunt is implanted, while allowing for movement along the distal portion in order to adjust the length of the shunt. The outwardly projecting formations furthermore create a fluid seal in the scleral channel.
In summary, a surgical method for treating glaucoma in a patient by lowering intraocular pressure in an eye of a patient, comprises:
The surgical method includes, prior to creating the passageway using the cutting blade, marking a point on the sclera in the pocket between the conjunctival/tenon's complex and the sclera at a predetermined distance from the limbus which may be approximately 3 mm from the limbus.
The surgical method may include creating the passageway through scleral tissue, from the predetermined position on the sclera to enter the chamber of the eye in a single step (as is illustrated in
Alternatively, the surgical method may include creating the passageway through scleral tissue, from the predetermined position on the sclera to enter the chamber of the eye in three steps as follows:
The shunt and method described hereinabove ameliorate the shortcomings of the prior art devices described above by reducing the maximal cross-sectional dimension of the fixation body to less than the maximal cross-sectional dimension of the surgical instrument used to create the scleral channel while still providing an adequate fluid seal. This reduces surgical invasiveness and the risk of device erosion and migration. The multi-bevelled and flat-bodied surgical blade of the present invention also assists a surgeon to easily create an appropriate scleral channel for the elongate duct of the shunt with a reduced risk of fluid leakage.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2022/00673 | Jan 2022 | ZA | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IB2023/050286 | 1/12/2023 | WO |